Tepotinib Yields High Partial Response Rates in NSCLC With MET Alterations
The MET alteration occurs in 3% to 4% of patients with the condition.
The MET alteration occurs in 3% to 4% of patients with the condition.
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.